Last 12 months
Inside the activity.
1 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 26, 2018 Filed Jul 30, 2018 22:06 UTC |
BURZIK CATHERINE MDirector
|
GrantCommon Stock | 1,696 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-024055 · form4.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,295 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 22:01 UTC |
Dockendorff Charles JDirector
|
GrantCommon Stock | 1,696 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-024053 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,880 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 21:55 UTC |
MEELIA RICHARD JDirector
|
GrantCommon Stock | 1,696 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-024049 · form4.xml · nonDerivative · entry 1 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,607 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 20:32 UTC |
Simon, ChristopherDirector · President & CEO
|
SaleCommon Stock | 5,139 | $89.31 | $458,964.09 |
DisclosureSEC source: 0001127602-18-022831 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,126 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 21:14 UTC |
Burke William P. Mr.EVP, Chief Financial Officer
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 5,717 | $0.00 Strike: $41.64 | $0.00 |
DisclosureSEC source: 0001127602-18-021961 · form4.xml · derivative · entry 4 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,153 Underlying: Common Stock · 5,717 shares Expires 2024-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 21:14 UTC |
Burke William P. Mr.EVP, Chief Financial Officer
|
SaleCommon Stock | 970 | $92.17 | $89,404.90 |
DisclosureSEC source: 0001127602-18-021961 · form4.xml · nonDerivative · entry 3 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,604 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 21:14 UTC |
Burke William P. Mr.EVP, Chief Financial Officer
|
SaleCommon Stock | 5,717 | $92.17 | $526,935.89 |
DisclosureSEC source: 0001127602-18-021961 · form4.xml · nonDerivative · entry 2 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,574 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 21:14 UTC |
Burke William P. Mr.EVP, Chief Financial Officer
|
Exercise / conversionCommon Stock | 5,717 | $41.64 | $238,055.88 |
DisclosureSEC source: 0001127602-18-021961 · form4.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 23:31 UTC |
Goldstein DanVP, Corporate Controller
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 1,903 | $0.00 Strike: $93.52 | $0.00 |
DisclosureSEC source: 0001127602-18-020841 · form4.xml · derivative · entry 2 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,903 Underlying: Common Stock · 1,903 shares Expires 2025-06-11 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 23:31 UTC |
Goldstein DanVP, Corporate Controller
|
GrantCommon Stock | 534 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-020841 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,556 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 23:35 UTC |
Bolorforosh SaidEVP, Chief Technology Officer
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 3,330 | $0.00 Strike: $93.52 | $0.00 |
DisclosureSEC source: 0001127602-18-020843 · form4.xml · derivative · entry 2 Bolorforosh Said · CIK 0001741776 · EVP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,330 Underlying: Common Stock · 3,330 shares Expires 2025-06-11 F3 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 23:35 UTC |
Bolorforosh SaidEVP, Chief Technology Officer
|
GrantCommon Stock | 935 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-020843 · form4.xml · nonDerivative · entry 1 Bolorforosh Said · CIK 0001741776 · EVP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 935 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 23:27 UTC |
Scanlan JacquelineSVP, Global Human Resources
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 5,233 | $0.00 Strike: $93.52 | $0.00 |
DisclosureSEC source: 0001127602-18-020839 · form4.xml · derivative · entry 2 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,233 Underlying: Common Stock · 5,233 shares Expires 2025-06-11 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 23:27 UTC |
Scanlan JacquelineSVP, Global Human Resources
|
GrantCommon Stock | 1,470 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-020839 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,253 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 23:22 UTC |
Basil Michelle LEVP and General Counsel
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 9,516 | $0.00 Strike: $93.52 | $0.00 |
DisclosureSEC source: 0001127602-18-020837 · form4.xml · derivative · entry 2 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,516 Underlying: Common Stock · 9,516 shares Expires 2025-06-11 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 23:22 UTC |
Basil Michelle LEVP and General Counsel
|
GrantCommon Stock | 2,673 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-020837 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,270 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 23:17 UTC |
Burke William P. Mr.EVP, Chief Financial Officer
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 9,278 | $0.00 Strike: $93.52 | $0.00 |
DisclosureSEC source: 0001127602-18-020833 · form4.xml · derivative · entry 2 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,278 Underlying: Common Stock · 9,278 shares Expires 2025-06-11 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 23:17 UTC |
Burke William P. Mr.EVP, Chief Financial Officer
|
GrantCommon Stock | 2,606 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-020833 · form4.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,574 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 23:13 UTC |
Simon, ChristopherDirector · President & CEO
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 40,443 | $0.00 Strike: $93.52 | $0.00 |
DisclosureSEC source: 0001127602-18-020831 · form4.xml · derivative · entry 2 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,443 Underlying: Common Stock · 40,443 shares Expires 2025-06-11 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 23:13 UTC |
Simon, ChristopherDirector · President & CEO
|
GrantCommon Stock | 11,361 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-020831 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,265 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 21:28 UTC |
Goldstein DanVP, Corporate Controller
|
SaleCommon Stock | 578 | $92.90 | $53,696.20 |
DisclosureSEC source: 0001127602-18-020725 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,022 F1 · shares: Sale effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:45 UTC |
Ryding Neil Mr.EVP, Global Manufacturing
|
SaleCommon Stock | 183 | $92.73 | $16,969.59 |
DisclosureSEC source: 0001127602-18-020492 · form4.xml · nonDerivative · entry 1 Ryding Neil Mr. · CIK 0001654614 · EVP, Global Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,226 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:40 UTC |
Burke William P. Mr.EVP, Chief Financial Officer
|
SaleCommon Stock | 425 | $92.73 | $39,410.25 |
DisclosureSEC source: 0001127602-18-020488 · form4.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,968 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:37 UTC |
Scanlan JacquelineSVP, Global Human Resources
|
SaleCommon Stock | 214 | $92.73 | $19,844.22 |
DisclosureSEC source: 0001127602-18-020486 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,783 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported and 473 shares purchased by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2018. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:31 UTC |
Basil Michelle LEVP and General Counsel
|
SaleCommon Stock | 457 | $92.73 | $42,377.61 |
DisclosureSEC source: 0001127602-18-020484 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,597 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported as well as 268 shares purchased by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2018. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:26 UTC |
Simon, ChristopherDirector · President & CEO
|
SaleCommon Stock | 1,941 | $92.73 | $179,988.93 |
DisclosureSEC source: 0001127602-18-020480 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,904 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:20 UTC |
Goldstein DanVP, Corporate Controller
|
SaleCommon Stock | 81 | $92.73 | $7,511.13 |
DisclosureSEC source: 0001127602-18-020476 · form4.xml · nonDerivative · entry 5 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 F2 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:20 UTC |
Goldstein DanVP, Corporate Controller
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 1,106 | $0.00 Strike: $41.64 | $0.00 |
DisclosureSEC source: 0001127602-18-020476 · form4.xml · derivative · entry 7 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,320 Underlying: Common Stock · 1,106 shares Expires 2024-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:20 UTC |
Goldstein DanVP, Corporate Controller
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,607 | $0.00 Strike: $34.42 | $0.00 |
DisclosureSEC source: 0001127602-18-020476 · form4.xml · derivative · entry 6 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,214 Underlying: Common Stock · 2,607 shares Expires 2023-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:20 UTC |
Goldstein DanVP, Corporate Controller
|
SaleCommon Stock | 1,106 | $95.14 | $105,224.84 |
DisclosureSEC source: 0001127602-18-020476 · form4.xml · nonDerivative · entry 4 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,681 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:20 UTC |
Goldstein DanVP, Corporate Controller
|
SaleCommon Stock | 2,607 | $95.14 | $248,029.98 |
DisclosureSEC source: 0001127602-18-020476 · form4.xml · nonDerivative · entry 3 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,787 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:20 UTC |
Goldstein DanVP, Corporate Controller
|
Exercise / conversionCommon Stock | 1,106 | $41.64 | $46,053.84 |
DisclosureSEC source: 0001127602-18-020476 · form4.xml · nonDerivative · entry 2 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:20 UTC |
Goldstein DanVP, Corporate Controller
|
Exercise / conversionCommon Stock | 2,607 | $34.42 | $89,732.94 |
DisclosureSEC source: 0001127602-18-020476 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 06, 2018 Filed Apr 10, 2018 22:29 UTC |
Goldstein DanVP, Corporate Controller
|
SaleCommon Stock | 210 | $72.19 | $15,159.90 |
DisclosureSEC source: 0001127602-18-014343 · form4.xml · nonDerivative · entry 3 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,681 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 22:05 UTC |
Scanlan JacquelineSVP, Global Human Resources
|
SaleCommon Stock | 114 | $72.23 | $8,234.22 |
DisclosureSEC source: 0001127602-18-010745 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,524 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes 516 shares purchased by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on October 31, 2017. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 22:01 UTC |
Basil Michelle LEVP and General Counsel
|
SaleCommon Stock | 389 | $72.23 | $28,097.47 |
DisclosureSEC source: 0001127602-18-010742 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,786 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes 293 shares purchased by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on October 31, 2017. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:07 UTC |
Zane Ellen MDirector
|
GrantCommon Stock | 1,301 | $65.86 | $85,683.86 |
DisclosureSEC source: 0001127602-18-002646 · form4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,301 F1 · shares: Restricted Stock Unit grant which vests 100% on the first anniversary of the grant date. The grant was made under the 2005 Long Term Incentive Compensation Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 01:56 UTC |
KROLL MARK WDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 7,118 | $0.00 Strike: $34.41 | $0.00 |
DisclosureSEC source: 0001127602-18-000896 · form4.xml · derivative · entry 3 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,118 shares Expires 2018-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 01:56 UTC |
KROLL MARK WDirector
|
SaleCommon Stock | 7,118 | $63.00 | $448,434.00 |
DisclosureSEC source: 0001127602-18-000896 · form4.xml · nonDerivative · entry 2 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,763 Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 01:56 UTC |
KROLL MARK WDirector
|
Exercise / conversionCommon Stock | 7,118 | $34.41 | $244,894.79 |
DisclosureSEC source: 0001127602-18-000896 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise and sale pursuant to a trading plan which was established consistent with the requirements of Rule 10b5-1. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC |
GRANADILLO PEDRO PDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 7,118 | $0.00 Strike: $34.41 | $0.00 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · derivative · entry 23 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,118 shares Expires 2018-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC |
GRANADILLO PEDRO PDirector
|
SaleCommon Stock | 40 | $57.10 | $2,284.00 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 22 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,381 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC |
GRANADILLO PEDRO PDirector
|
SaleCommon Stock | 200 | $57.09 | $11,418.00 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 21 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,421 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC |
GRANADILLO PEDRO PDirector
|
SaleCommon Stock | 200 | $57.08 | $11,416.00 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 20 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,621 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC |
GRANADILLO PEDRO PDirector
|
SaleCommon Stock | 100 | $57.07 | $5,707.49 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 19 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,821 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC |
GRANADILLO PEDRO PDirector
|
SaleCommon Stock | 760 | $57.07 | $43,373.20 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 18 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,921 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC |
GRANADILLO PEDRO PDirector
|
SaleCommon Stock | 200 | $57.06 | $11,412.00 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 17 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,681 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC |
GRANADILLO PEDRO PDirector
|
SaleCommon Stock | 4,100 | $57.06 | $233,925.50 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 16 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,881 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC |
GRANADILLO PEDRO PDirector
|
SaleCommon Stock | 9 | $57.05 | $513.45 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 15 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,981 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC |
GRANADILLO PEDRO PDirector
|
SaleCommon Stock | 100 | $57.03 | $5,703.00 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 14 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,990 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.